Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria
Division of Cardiothoracic and Vascular Anesthesia, Medical University of Vienna, Austria
Multimed Man Cardiothorac Surg. 2022 Nov 4;2022. doi: 10.1510/mmcts.2022.082.
The recent CE mark approval of a novel transapical transcatheter beating-heart replacement system, anchored by an apical pad, expanded the therapeutic options for patients with a significantly diseased mitral valve who are not eligible for conventional surgery. However, this self-expandable bioprosthesis is-despite promising data from the first European real-world experience-not approved for patients with severe mitral annular calcification. In this video tutorial, we provide a step-by-step description of an off-label transapical mitral valve replacement in a patient with severe degenerative mitral valve disease and limited alternative treatment options.
最近，一种新型经心尖经导管跳动心脏置换系统获得 CE 标志批准，该系统通过一个心尖垫固定，为那些不符合传统手术适应证的严重二尖瓣病变患者提供了更多的治疗选择。然而，尽管来自首次欧洲真实世界经验的有希望的数据，但这种自扩张生物假体不适用于严重二尖瓣环钙化的患者。在本视频教程中，我们为一位患有严重退行性二尖瓣疾病且替代治疗选择有限的患者提供了经心尖二尖瓣置换术的分步描述。
